Consists of Diphtheria Toxoid, Haemophilus B Conjugate Vaccine, Pertussis Toxoid, Tetanus Toxoid
Uses of Diphtheria Toxoid (Easyfour-TT Paediatric Vaccine) in details
Diphtheria Toxoid (Easyfour-TT Paediatric Vaccine) is a vaccine used to protect against the infectious disease diphtheria. It is used in combination with other vaccines that offer protection against disease like pertussis (whooping cough) and tetanus (DPT vaccine).
Diphtheria Toxoid (Easyfour-TT Paediatric Vaccine) side effects
Neurological disturbances, Pain, Fever, Flushing, Decreased blood pressure, Skin redness, Tachycardia, Tenderness, Urticaria
What is Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine)?
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) is an active immunizing agent that is used to prevent infection caused by the Haemophilus influenza type b (Hib) bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) is prepared by adding a diphtheria, meningococcal, or tetanus-related substance to the process. However, this vaccine does not take the place of the regular vaccines for diphtheria, tetanus, or meningococcus that children and adults should receive. All of the haemophilus b conjugate vaccines work the same way, but they may be given at different ages or using a different schedule.
Infections with Haemophilus influenza type b (Hib) bacteria can cause life-threatening illnesses, such as meningitis (a brain disease), epiglottitis (a throat disease that can cause suffocation), pericarditis (a heart disease), pneumonia (a lung disease), and septic arthritis (a bone and joint disease). Hib meningitis may cause death or leave the child with serious and permanent damage, such as mental retardation, deafness, epilepsy, or partial blindness.
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) is recommended for all children 2 months to 5 years of age (i.e., up to the 6th birthday).
The Hiberix® vaccine is used as a booster dose for children who have already received the primary series with a Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine). The vaccine will "boost" or increase the protection that the child had from an earlier dose.
This vaccine is to be administered only by or under the direct supervision of your doctor.
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) indications
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (Diphtheria CRMProtein Conjugate) Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) is indicated for the immunization of children 2 months to 71 months of age against invasive diseases caused by H. influenzae type b.
As with any vaccine, Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) may not protect 100% of individuals receiving the vaccine.
The American Academy of Pediatrics (AAP), the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) encourage the routine simultaneous administration of Haemophilus influenzae type b vaccines with other currently recommended vaccines, but at different sites.
How should I use Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine)?
Use Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) at home, carefully follow the injection procedures taught to you by your health care provider.
- If you miss a dose of Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine), contact your doctor.
Ask your health care provider any questions you may have about how to use Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine).
Uses of Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) in details
Use: Labeled Indications
Active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib):
ActHIB: Immunization of infants and children 2 months to 5 years of age.
Hiberix: Immunization of infants and children 6 weeks to 4 years of age (prior to fifth birthday).
PedvaxHIB: Routine vaccination of infants and children 2 to 71 months of age.
The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for the following (CDC/ACIP [Briere 2014]):
- Routine immunization of all infants and children through age 59 months
- Unimmunized (defined as those who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age) children 12 to 59 months including chemotherapy recipients, anatomic or functional asplenia (including sickle cell disease), HIV infection, immunoglobulin deficiency or early component complement deficiency
Efficacy data are not available for use in older children and adults with chronic conditions associated with an increased risk of Hib disease. However, use may be considered for:
- Unimmunized (defined as those who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age) children ≥5 years, adolescents and adults with functional or anatomic asplenia, (including sickle cell disease)
- Unimmunized (defined as those who have not received a primary series and booster dose or at least 1 dose of a Hib vaccine after 14 months of age) children ≥5 years and adolescents with HIV infection
- Children <5 years undergoing chemotherapy or radiation treatment
- Successful hematopoietic stem cell transplant recipients
- Children ≥15 months and adolescents undergoing elective splenectomy
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) dosage
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) is for intramuscular use only.
Any parenteral drug product should be inspected visually for particulate matter and/or discoloration prior to administration whenever solution and container permit. If these conditions exist, or if cloudy, Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) should not be administered.
Before injection, the skin over the site to be injected should be cleansed with a suitable germicide. After insertion of the needle, aspirate to help avoid inadvertent injection into a blood vessel.
The vaccine should be injected intramuscularly, preferably into the midlateral muscles of the thigh or deltoid, with care to avoid major peripheral nerve trunks. Do not inject in the gluteal area.
The vaccine is to be administered immediately after being drawn up into a syringe. Single dose 0.5 mL vial contains no preservative. Use one dose per vial; do not re-enter vial. Discard unused portions.
The vaccine is not to be mixed with other vaccines/products in the same syringe.
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) is indicated for children 2 months to 71 months of age for the prevention of invasive Haemophilus b disease. For infants 2 to 6 months of age, the immunizing dose is three separate injections of 0.5 mL given at approximately 2-month intervals. Previously unvaccinated infants from 7 through 11 months of age should receive two separate injections approximately 2 months apart. Children from 12 through 14 months of age who have not been vaccinated previously receive one injection. All vaccinated children receive a single booster dose at 15 months of age or older, but not less than 2 months after the previous dose. Previously unvaccinated children 15 to 71 months of age receive a single injection of Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate).
Each dose of 0.5 mL is formulated to contain 10 µg of purified Haemophilus b saccharide and approximately 25 µg of CRM protein.
Storage
DO NOT FREEZE. Store refrigerated away from freezer compartments at 2°C-8°C (36°F-46°F). Discard if the vaccine has been frozen.
How supplied
Vial, 1 Dose (5 per package) – Product No. 0005-0104-32
REFERENCES
32. Recommendations of the AAP: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization of infants and children 2 months of age and older: update. Pediatrics. 1991;88:169-172.
33. Recommendation of the ACIP: Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. MMWR. 1991;40:1-7.
34. Centers for Disease Control and Prevention. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR. 2002;51(No. RR-2);1-36.
35. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000: 26, 266-72.
55. Greenberg DP, Lieberman JM, Marcy SM, et al. Enhanced antibody responses in infants given different sequences of heterogenous Haemophilus influenzae type b conjugate vaccines. J Pediatr. 1995;126:206-11.
56. Anderson EL, Decker MD, Englund JA, et al. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA. 1995;273:849-53.
57. Scheifele D, Law B, Mitchell L, Ochnio J. Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine. 1996;14(15):1399-1406.
This product's label may have been revised after this insert was used in production. For further product information and current package insert, please visit www.wyeth.com or call our medical communications department toll free at 1-800-934-5556. Manufactured by: Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101.
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) interactions
See also:
What other drugs will affect Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine)?
Children receiving therapy with immunosuppressive agents (large amounts of corticosteroids,
antimetabolites, alkylating agents, cytotoxic agents) may not respond optimally to active
immunization.37,38,39
As with other intramuscular injections, Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) should be given with caution to children on
anticoagulant therapy.
No impairment of the antibody response to the individual antigens was demonstrated when
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) was given at the same time but at separate sites as diphtheria tetanus pertussis vaccine
(DTP) plus oral polio vaccine (OPV) to children 2 to 20 months of age or measles-mumpsrubella
(MMR) to children 15 ± 1 month of age.20,43,44
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) side effects
Adverse reactions associated with Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) have been evaluated in 401 infants who were vaccinated initially at 1 to 6 months of age and were given 1,118 doses independent of DTP vaccine. Observations were made during the day of vaccination and days 1 and 2 postvaccination. A temperature > 38.3°C was recorded at least once during the observation period following 2% of the vaccinations. Local erythema, warmth, or swelling ( ≥ 2 cm) was observed following 3.3% of vaccinations. The incidence of temperature > 38.3°C was greater during the first postvaccination day than during the day of vaccination or the second postvaccination day. The incidence of local erythema, warmth, or swelling was similar during the day of vaccination and the first postvaccination day; it was lower during the second postvaccination day. All side effects have been infrequent, mild, and transient with no serious sequelae (Table 1). No difference in the rates of these complaints was reported after dose 1, 2, or 3.
TABLE 1: Number of Subjects (Percent) Manifesting Side Effects Associated with Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) Administered Independently from DTP* (Infants Vaccinated Initially at 1-6 Months of Age)
| Dose 1 n = 401 | Dose 2 n = 383 | Dose 3 n = 334 | |||||||
| Symptoms | Same Day As Vacc. | +1 Day | +2 Days | Same Day As Vacc. | +1 Day | +2 Days | Same Day As Vacc. | +1 Day | +2 Days |
| Temp > 38.3°C | 0 | 2 | 2 | 2 | 3 | 2 | 2 | 6 | 5 |
| - | < 1% | < 1% | < 1% | < 1% | < 1% | < 1% | 1.8% | 1.5% | |
| Redness > 2 cm | 1 | 0 | 0 | 1 | 6 | 0 | 5 | 4 | 0 |
| < 1% | - | - | < 1% | 1.6% | - | 1.5% | 1.2% | - | |
| Warmth ≥ 2 cm | 1 | 1 | 0 | 2 | 1 | 0 | 1 | 6 | 0 |
| < 1% | < 1% | - | < 1% | < 1% | - | < 1% | 1.8% | - | |
| Swelling ≥ 2 cm | 5 | 1 | 0 | 2 | 2 | 0 | 1 | 0 | 0 |
| 1.2% | < 1% | - | < 1% | < 1% | - | < 1% | - | - | |
| *DTP and Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) given 2 weeks apart with DTP having been given first. |
The following complaints were also observed after 1,118 vaccinations with Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) : irritability (133), sleepiness (91), prolonged crying [ ≥ 4 hours] (38), appetite loss (23), vomiting (9), diarrhea (2), and rash (1).
Additional safety data with Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) are available from the efficacy studies conducted in young infants. The VAERS FDA web site is: http://www.fda.gov/cber/vaers/vaers.htm
The VAERS toll-free number for VAERS forms and information is 800-822-7967.
Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) contraindications
Hypersensitivity to any component of the vaccine, including Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine), is a contraindication to the use of Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate).
The occurrence of an allergic or anaphylactic reaction following a prior dose of Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate) is a contraindication to the use of Haemophilus B Conjugate Vaccine (Easyfour-TT Paediatric Vaccine) (diphtheria crm197 protein conjugate).
Uses of Pertussis Toxoid (Easyfour-TT Paediatric Vaccine) in details
Pertussis.
Pertussis Toxoid (Easyfour-TT Paediatric Vaccine) side effects
Diarrhoea, Fever, Injection site pain, Skin redness, Soreness, Swelling, Tenderness, Vomiting
What is Tetanus Toxoid (Easyfour-TT Paediatric Vaccine)?
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) is used to prevent tetanus (also known as lockjaw). Tetanus is a serious illness that causes convulsions (seizures) and severe muscle spasms that can be strong enough to cause bone fractures of the spine. Tetanus causes death in 30 to 40 percent of cases.
Immunization against tetanus is recommended for all infants 6 to 8 weeks of age and older, all children, and all adults. Immunization against tetanus consists first of a series of either 3 or 4 injections, depending on which type of Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) you receive. In addition, it is very important that you get a booster injection every 10 years for the rest of your life. Also, if you get a wound that is unclean or hard to clean, you may need an emergency booster injection if it has been more than 5 years since your last booster. In recent years, two-thirds of all tetanus cases have been in persons 50 years of age and older. A tetanus infection in the past does not make you immune to tetanus in the future.
This vaccine is to be administered only by or under the supervision of your doctor or other health care professional.
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) indications
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) vaccine is indicated for active immunization of children 7 years of age or older, and adults, against tetanus, wherever combined antigen preparations are not indicated.
This vaccine is NOT to be used for the treatment of tetanus infection.
As with any vaccine, vaccination with Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) may not protect 100% of susceptible individuals.
If passive immunization is required, Tetanus Immune Globulin (Human) (TIG) should be used.
How should I use Tetanus Toxoid (Easyfour-TT Paediatric Vaccine)?
Use Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) is administered as an injection at your doctor's office, hospital, or clinic.
- If you miss a dose of Tetanus Toxoid (Easyfour-TT Paediatric Vaccine), contact your doctor immediately.
Ask your health care provider any questions you may have about how to use Tetanus Toxoid (Easyfour-TT Paediatric Vaccine).
Uses of Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) in details
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) is the vaccine given for prevention of tetanus (a bacterial infection with symptoms of tightening of muscles of the body and locked jaw).
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) dosage
Dosing: Adult
Note: Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) (adsorbed) has been discontinued in the US for more than 1 year.
Note: In most patients, Td is the recommended product for primary immunization, booster doses, and tetanus immunization in wound management (refer to Diphtheria and Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) monograph).
Primary immunization: IM: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose
Routine booster dose: Recommended every 10 years
Tetanus prophylaxis in wound management: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated, the immunization status of the patient, proper use of Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a Tetanus Toxoid (Easyfour-TT Paediatric Vaccine)-containing vaccine should not receive a Tetanus Toxoid (Easyfour-TT Paediatric Vaccine)-containing vaccine until >10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.
History of Tetanus Immunization Doses | Clean, Minor Wounds | All Other Wounds | No | ||
|---|---|---|---|---|---|
History of Tetanus Immunization (Doses): Uncertain or <3 doses
Clean, Minor Wounds: Administer a Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) containing vaccine. For children <7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone. For children ≥7 years of age and Adults, Td preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.
Other Wounds (such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite): Administer a Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) containing vaccine and TIG. For children <7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone. For children ≥7 years of age and Adults, Td preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.
History of Tetanus Immunization (Doses): 3 or more doses
Clean, Minor Wounds: Administer a Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) containing vaccine if ≥10 years since last dose. For children <7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone. For children ≥7 years of age and Adults, Td preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.
Other Wounds (such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite): Administer a Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) containing vaccine if ≥5 years since last dose. For children <7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone. For children ≥7 years of age and Adults, Td preferred to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.
Abbreviations: DT = Diphtheria and Tetanus Toxoids (formulation for age ≤6 years); DTaP = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age ≤6 years; Daptacel®, Infanrix®, Tripedia®); Td = Diphtheria and Tetanus Toxoids (formulation for age ≥7 years; Decavac®, Tenivac™); TT= Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) (adsorbed [formulation for age ≥7 years]); Tdap = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel® or Boostrix® [formulations for age ≥7 years]); TIG = Tetanus Immune Globulin
Adapted from the Yellow Book 2010, Chapter 2, Routine Vaccine-Preventable Diseases, Tetanus; Available at www.cdc.gov/yellowbook and MMWR, 2006, 55:RR-17.
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) interactions
See also:
What other drugs will affect Tetanus Toxoid (Easyfour-TT Paediatric Vaccine)?
If passive immunization for tetanus is needed, TIG (Human) is the product of choice. It provides longer protection than antitoxin of animal origin and causes few adverse reactions. The currently recommended prophylactic dose of TIG (Human) for wounds of average severity is 250 units intramuscularly. When Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) vaccine and TIG (Human) are given concurrently, separate syringes and separate sites should be used. The ACIP recommends the use of only adsorbed toxoid in this situation.
As with other intramuscular injections, use with caution in patients on anticoagulant therapy.
Immunosuppressive therapies may reduce the immune response to vaccines.
REFERENCES
1. Recommendations of the Immunization Practices Advisory Committee (ACIP). Diphtheria, Tetanus, and Pertussis: Recommendations for vaccine use and other preventive measures. MMWR 40: No. RR-10, 1991
6. Stratton KR, et al. Adverse events associated with childhood vaccines. Evidence Bearing on Causality. National Academy Press, Washington, DC, 1994
8. CDC. Vaccine Adverse Event Reporting System – United States. MMWR 39: 730-733, 1990
9. CDC. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. MMWR 37: 197-200, 1988
10. Food and Drug Administration. New reporting requirements for vaccine adverse events. FDA Drug Bull 18 (2), 16-18, 1988
13. Rutledge SL, et al. Neurological complications of immunizations. J. Pediatr 109: 917-924, 1986
14. Wilson GS. The Hazards of Immunization. Allergic manifestations: post-vaccinal neuritis. pp 153-156, 1967
15. Tsairis P, et al. Natural history of brachial plexus neuropathy. Arch Neurol 27: 109-117, 1972
16. Blumstein GI, et al. Peripheral neuropathy following Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) administration. JAMA 198: 1030-1031, 1966
17. Pollard JD, et al. Relapsing neuropathy due to Tetanus Toxoid (Easyfour-TT Paediatric Vaccine): report of a case. J Neurol Sci 37: 112-125, 1978
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) side effects
See also:
What are the possible side effects of Tetanus Toxoid (Easyfour-TT Paediatric Vaccine)?
Body System As a Whole
Adverse reactions may be local and include redness, warmth, edema, induration with or without tenderness as well as urticaria, and rash. Malaise, transient fever, pain, hypotension, nausea and arthralgia may develop in some patients after the injection. Arthus-type hypersensitivity reactions, characterized by severe local reactions (generally starting 2 to 8 hours after an injection) may occur, particularly in persons who have received multiple prior boosters.
Health-care providers also should report these events to Director of Scientific and Medical Affairs, Aventis Pasteur Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-2463.
Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) contraindications
HYPERSENSITIVITY TO ANY COMPONENT OF THE VACCINE, INCLUDING THIMEROSAL, A MERCURY DERIVATIVE, IS A CONTRAINDICATION FOR FURTHER USE OF THIS VACCINE.
It is a contraindication to use this or any other related vaccine after a serious adverse reaction temporally associated with a previous dose, including an anaphylactic reaction.
A history of systemic allergic or neurologic reactions following a previous dose of Tetanus Toxoid (Easyfour-TT Paediatric Vaccine) vaccine is an absolute contraindication for further use.
REFERENCES
1. Recommendations of the Immunization Practices Advisory Committee (ACIP). Diphtheria, Tetanus, and Pertussis: Recommendations for vaccine use and other preventive measures. MMWR 40: No. RR-10, 1991
5. Wilson GS. The Hazards of Immunization. Provocation poliomyelitis. 270-274, 1967
Active ingredient matches for Easyfour-TT Paediatric Vaccine:
Diphtheria Toxoid/Haemophilus B Conjugate Vaccine/Pertussis Toxoid/Tetanus Toxoid
| Unit description / dosage (Manufacturer) | Price, USD |
| Easyfour-TT Paediatric Vaccine (Panacea Biotec Ltd) | $ 7.47 |
List of Easyfour-TT Paediatric Vaccine substitutes (brand and generic names): | |
| Diphtheria Toxoid/Haemophilus B Conjugate Vaccine/Pertussis Toxoid/Tetanus Toxoid | |
| Easy Six Vaccine | |
| Easy Six Vaccine (Panacea Biotec Ltd) | $ 28.83 |
| QUADROVAX | |
| QUADROVAX INJECTION 1 vial / 1 ML injection each (Serum Institute Of India Ltd) | $ 5.17 |
References
- PubChem. "Tetanus toxoid". https://pubchem.ncbi.nlm.nih.gov/sub... (accessed September 17, 2018).
- DrugBank. "Clostridium tetani toxoid antigen (formaldehyde inactivated) - DrugBank". http://www.drugbank.ca/drugs/DB10583 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Easyfour-TT Paediatric Vaccine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Easyfour-TT Paediatric Vaccine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 16-29 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
